A protease inhibitor (PI) that circumvents the problems of earlier PIs such as certain adverse events, a complex dosing regimen, and toxicities such as lipid disturbances and glucose metabolism will soon be available to those infected with HIV. The FDA recently approved atazanavir (Reyataz, Bristol-Myers Squibb) for use in combination with other antiretroviral agents for the treatment of HIV infection. Atazanavir will be available in pharmacies sometime this month.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.